Nu Med Plus Net Income
| NUMD Stock | USD 0.01 0.01 29.00% |
As of the 2nd of February, Nu-Med Plus owns the Information Ratio of (0.1), mean deviation of 3.38, and Market Risk Adjusted Performance of (0.45). In relation to fundamental indicators, the technical analysis model lets you check practical technical drivers of Nu Med Plus, as well as the relationship between them. Strictly speaking, you can use this information to find out if the firm will indeed mirror its model of historical prices and volume patterns, or the prices will eventually revert. We have collected data for twelve technical drivers for Nu-Med Plus, which can be compared to its peers in the sector. Please verify Nu Med Plus market risk adjusted performance, variance, as well as the relationship between the Variance and value at risk to decide if Nu Med Plus is priced correctly, providing market reflects its prevailing price of 0.0142 per share. As Nu Med Plus appears to be a penny stock we also strongly suggest to check its jensen alpha numbers.
Nu-Med Plus' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Nu-Med Plus' valuation are provided below:Nu Med Plus does not now have any fundamental measures for analysis. This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. Nu-Med |
Nu-Med Plus 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Nu-Med Plus' otc stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Nu-Med Plus.
| 11/04/2025 |
| 02/02/2026 |
If you would invest 0.00 in Nu-Med Plus on November 4, 2025 and sell it all today you would earn a total of 0.00 from holding Nu Med Plus or generate 0.0% return on investment in Nu-Med Plus over 90 days. Nu-Med Plus is related to or competes with Talis Biomedical, USA Equities, and Kelyniam Global. Nu-Med Plus, Inc., a medical device company, engages in the design, development, enhancement, and commercialization of m... More
Nu-Med Plus Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Nu-Med Plus' otc stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Nu Med Plus upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.1) | |||
| Maximum Drawdown | 55.96 | |||
| Value At Risk | (13.33) |
Nu-Med Plus Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Nu-Med Plus' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Nu-Med Plus' standard deviation. In reality, there are many statistical measures that can use Nu-Med Plus historical prices to predict the future Nu-Med Plus' volatility.| Risk Adjusted Performance | (0.06) | |||
| Jensen Alpha | (0.86) | |||
| Total Risk Alpha | (1.20) | |||
| Treynor Ratio | (0.46) |
Nu-Med Plus February 2, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.06) | |||
| Market Risk Adjusted Performance | (0.45) | |||
| Mean Deviation | 3.38 | |||
| Coefficient Of Variation | (1,070) | |||
| Standard Deviation | 8.42 | |||
| Variance | 70.86 | |||
| Information Ratio | (0.1) | |||
| Jensen Alpha | (0.86) | |||
| Total Risk Alpha | (1.20) | |||
| Treynor Ratio | (0.46) | |||
| Maximum Drawdown | 55.96 | |||
| Value At Risk | (13.33) | |||
| Skewness | 1.48 | |||
| Kurtosis | 14.64 |
Nu Med Plus Backtested Returns
Nu Med Plus retains Efficiency (Sharpe Ratio) of -0.0956, which conveys that the firm had a -0.0956 % return per unit of price deviation over the last 3 months. Nu-Med Plus exposes twenty different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please verify Nu-Med Plus' Information Ratio of (0.1), market risk adjusted performance of (0.45), and Mean Deviation of 3.38 to check out the risk estimate we provide. The company owns a Beta (Systematic Risk) of 1.72, which conveys a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Nu-Med Plus will likely underperform. At this point, Nu Med Plus has a negative expected return of -0.82%. Please make sure to verify Nu-Med Plus' variance and the relationship between the value at risk and relative strength index , to decide if Nu Med Plus performance from the past will be repeated at future time.
Auto-correlation | -0.21 |
Weak reverse predictability
Nu Med Plus has weak reverse predictability. Overlapping area represents the amount of predictability between Nu-Med Plus time series from 4th of November 2025 to 19th of December 2025 and 19th of December 2025 to 2nd of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Nu Med Plus price movement. The serial correlation of -0.21 indicates that over 21.0% of current Nu-Med Plus price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.21 | |
| Spearman Rank Test | -0.09 | |
| Residual Average | 0.0 | |
| Price Variance | 0.0 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Based on the recorded statements, Nu Med Plus reported net income of (830,061). This is 100.24% lower than that of the Healthcare sector and 100.35% lower than that of the Medical Devices industry. The net income for all United States stocks is 100.15% higher than that of the company.
Nu-Med Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Nu-Med Plus' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the otc stocks which would be a good addition to a portfolio. Peer analysis of Nu-Med Plus could also be used in its relative valuation, which is a method of valuing Nu-Med Plus by comparing valuation metrics of similar companies.Nu Med is currently under evaluation in net income category among its peers.
Nu-Med Fundamentals
| Return On Equity | -545.23 | |||
| Return On Asset | -6.62 | |||
| Current Valuation | 1.63 M | |||
| Shares Outstanding | 81.35 M | |||
| Shares Owned By Insiders | 61.99 % | |||
| Price To Earning | 19.00 X | |||
| Price To Book | 49.86 X | |||
| EBITDA | (808.68 K) | |||
| Net Income | (830.06 K) | |||
| Cash And Equivalents | 2.54 K | |||
| Total Debt | 2.06 K | |||
| Debt To Equity | 0.04 % | |||
| Current Ratio | 0.03 X | |||
| Book Value Per Share | (0) X | |||
| Cash Flow From Operations | (206.83 K) | |||
| Earnings Per Share | (0.01) X | |||
| Beta | 0.52 | |||
| Market Capitalization | 1.14 M | |||
| Total Asset | 22.16 K | |||
| Retained Earnings | (2.41 M) | |||
| Working Capital | (433.44 K) | |||
| Current Asset | 57.17 K | |||
| Current Liabilities | 490.62 K | |||
| Z Score | 38.4 | |||
| Net Asset | 22.16 K |
About Nu-Med Plus Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Nu Med Plus's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Nu-Med Plus using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Nu Med Plus based on its fundamental data. In general, a quantitative approach, as applied to this otc stock, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in Nu-Med OTC Stock
Nu-Med Plus financial ratios help investors to determine whether Nu-Med OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Nu-Med with respect to the benefits of owning Nu-Med Plus security.